ValuEngine upgraded shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) from a strong sell rating to a sell rating in a research note published on Tuesday.
Other analysts have also recently issued research reports about the company. Zacks Investment Research raised Neos Therapeutics from a hold rating to a buy rating and set a $9.00 price target for the company in a research report on Tuesday, June 13th. BMO Capital Markets reiterated an outperform rating and set a $15.00 price objective on shares of Neos Therapeutics in a research note on Tuesday. Finally, Cowen and Company started coverage on Neos Therapeutics in a research note on Wednesday, April 5th. They set an outperform rating and a $20.00 price objective for the company.
Neos Therapeutics (NASDAQ:NEOS) traded down 4.05% during mid-day trading on Tuesday, reaching $7.10. The company had a trading volume of 214,435 shares. Neos Therapeutics has a 52 week low of $4.85 and a 52 week high of $9.99. The stock’s 50-day moving average price is $7.87 and its 200 day moving average price is $6.82. The firm’s market capitalization is $160.18 million.
Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.87) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.94) by $0.07. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%. The company had revenue of $5.63 million during the quarter. On average, equities research analysts predict that Neos Therapeutics will post ($3.23) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://transcriptdaily.com/2017/06/23/neos-therapeutics-inc-neos-raised-to-sell-at-valuengine.html.
Several institutional investors have recently added to or reduced their stakes in the stock. Mission Wealth Management LLC bought a new position in Neos Therapeutics during the first quarter worth $122,000. Teachers Advisors LLC raised its position in shares of Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares in the last quarter. Sheaff Brock Investment Advisors LLC acquired a new position in shares of Neos Therapeutics during the first quarter valued at $216,000. Wells Fargo & Company MN raised its position in shares of Neos Therapeutics by 130.3% in the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock valued at $346,000 after buying an additional 27,174 shares in the last quarter. Finally, Hunter Associates Investment Management LLC acquired a new position in shares of Neos Therapeutics during the first quarter valued at $360,000. Institutional investors and hedge funds own 40.16% of the company’s stock.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.